NM_007294.4:c.884A>G
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 0P and 2B. BP4BP6
The NM_007294.4(BRCA1):c.884A>G(p.Asp295Gly) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000287 in 1,461,868 control chromosomes in the GnomAD database, including 1 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. D295Y) has been classified as Likely benign.
Frequency
Consequence
NM_007294.4 missense
Scores
Clinical Significance
Conservation
Publications
- breast-ovarian cancer, familial, susceptibility to, 1Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, ClinGen, Labcorp Genetics (formerly Invitae), Genomics England PanelApp
- Fanconi anemia, complementation group SInheritance: AR Classification: DEFINITIVE, STRONG, MODERATE, LIMITED Submitted by: G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
- pancreatic cancer, susceptibility to, 4Inheritance: AD Classification: MODERATE Submitted by: Genomics England PanelApp
- hereditary breast ovarian cancer syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Fanconi anemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -2 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_007294.4. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| BRCA1 | NM_007294.4 | MANE Select | c.884A>G | p.Asp295Gly | missense | Exon 10 of 23 | NP_009225.1 | ||
| BRCA1 | NM_001407581.1 | c.884A>G | p.Asp295Gly | missense | Exon 10 of 24 | NP_001394510.1 | |||
| BRCA1 | NM_001407582.1 | c.884A>G | p.Asp295Gly | missense | Exon 10 of 24 | NP_001394511.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| BRCA1 | ENST00000357654.9 | TSL:1 MANE Select | c.884A>G | p.Asp295Gly | missense | Exon 10 of 23 | ENSP00000350283.3 | ||
| BRCA1 | ENST00000471181.7 | TSL:1 | c.884A>G | p.Asp295Gly | missense | Exon 10 of 24 | ENSP00000418960.2 | ||
| BRCA1 | ENST00000470026.6 | TSL:1 | c.884A>G | p.Asp295Gly | missense | Exon 10 of 23 | ENSP00000419274.2 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD2 exomes AF: 0.0000796 AC: 20AN: 251246 AF XY: 0.000118 show subpopulations
GnomAD4 exome AF: 0.0000287 AC: 42AN: 1461868Hom.: 1 Cov.: 34 AF XY: 0.0000440 AC XY: 32AN XY: 727228 show subpopulations
Age Distribution
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
not provided Uncertain:1Benign:3
In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Also known as 1003A>G; This variant is associated with the following publications: (PMID: 33471991, 34218100, 9582019, 9788437, 9926942, 15343273, 20215511, 26541979, 31954625, 21156238)
Hereditary cancer-predisposing syndrome Uncertain:1Benign:2
This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
This missense variant replaces aspartic acid with glycine at codon 295 of the BRCA1 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in at least two individuals affected with breast cancer, an individual affected with ovarian cancer and one individual unaffected with cancer (PMID: 21156238, 26541979, 34218100), and this variant also has been detected in a breast cancer case-control meta-analysis in 0/60466 cases and 4/53461 unaffected individuals (PMID: 33471991; Leiden Open Variation Database DB-ID BRCA1_005730). This variant has been identified in 20/251246 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Missense variant in a coldspot region where missense variants are very unlikely to be pathogenic (PMID:31911673).
Hereditary breast ovarian cancer syndrome Uncertain:2
This sequence change replaces aspartic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 295 of the BRCA1 protein (p.Asp295Gly). This variant is present in population databases (rs772684048, gnomAD 0.06%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with a personal and/or family history of breast and/or ovarian cancer (PMID: 21156238, 31954625, 34218100). ClinVar contains an entry for this variant (Variation ID: 233188). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt BRCA1 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
not specified Uncertain:1
Variant summary: BRCA1 c.884A>G (p.Asp295Gly) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-05 in 251246 control chromosomes, predominantly at a frequency of 0.00065 within the South Asian subpopulation in the gnomAD database. This frequency is not significantly higher than expected for a pathogenic variant in BRCA1 causing Hereditary Breast and Ovarian Cancer (8e-05 vs 0.001), allowing no conclusion about variant significance. c.884A>G has been reported in the literature in individuals affected with breast and/or ovarian cancer (Manguoglu_2010, Hasmad_2016), but also in a healthy control subject (Manguoglu_2010). These reports do not provide unequivocal conclusions about association of the variant with Hereditary Breast and Ovarian Cancer. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar (evaluation after 2014) and cited the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance.
Breast-ovarian cancer, familial, susceptibility to, 1;C3280442:Pancreatic cancer, susceptibility to, 4;C4554406:Fanconi anemia, complementation group S Uncertain:1
BRCA1-related cancer predisposition Uncertain:1
This missense variant replaces aspartic acid with glycine at codon 295 of the BRCA1 protein. Computational prediction is inconclusive regarding the impact of this variant on protein structure and function. To our knowledge, functional studies have not been reported for this variant. This variant has been reported in at least two individuals affected with breast cancer, an individual affected with ovarian cancer and one individual unaffected with cancer (PMID: 21156238, 26541979, 34218100), and this variant also has been detected in a breast cancer case-control meta-analysis in 0/60466 cases and 4/53461 unaffected individuals (PMID: 33471991; Leiden Open Variation Database DB-ID BRCA1_005730). This variant has been identified in 20/251246 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance.
Malignant tumor of breast Uncertain:1
The BRCA1 c.884A>G variant was not identified in the literature. The variant was identified in dbSNP (ID: rs772684048) as “With Uncertain Significance allele”, Clinvitae database (as uncertain significance), and the ClinVar database (as uncertain significance, by Ambry Genetics). The variant was not found in the Fanconi Anemia Mutation Database (LOVD), LOVD-IARC database, ARUP Laboratories BRCA Mutations Database, COSMIC, GeneInsight COGR database, the BIC database, and UMD. This variant was identified in the Exome Aggregation Consortium database (August 8th, 2016) in 8 of 121358 chromosomes (freq. 6.59X10-5) in the following populations: South Asian in 8 of 16504 chromosomes (freq. 0.00048), but was not seen in African, East Asian, Finnish, European (Non-Finnish), and Latino populations, although this low number of observations and low frequency is not substantive enough to determine the prevalence of the variant in the general population and its relationship to disease. The p.Asp295 residue is not conserved in mammals and computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) provide inconsistent predictions regarding the impact to the protein; this information is not very predictive of pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at